New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:10 EDTCIDM, LEN, FSLR, XONE, BGMD, SNTA, SSYS, GES, TLYS, BURL, GSK, DDDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%... Lennar (LEN), up 2%... BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial... First Solar (FSLR), up 3.5% after the company's price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%... Tilly's (TLYS), down 7%... ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint... Cinedigm Digital (CIDM), down 12% after filing to sell common stock.
News For GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
10:54 EDTXONE, DDD, SSYSStratasys shares at 'compelling entry point' after pullback, says Canaccord
Subscribe for More Information
07:27 EDTSSYSStratasys weakness a buying opportunity, says Canaccord
Subscribe for More Information
January 27, 2015
10:00 EDTDDDOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
08:39 EDTSSYS, DDDJefferies cuts 3D Systems ahead of Q4 results
Subscribe for More Information
05:02 EDTDDD3D Systems downgraded to Hold from Buy at Jefferies
Subscribe for More Information
January 26, 2015
11:50 EDTFSLRSolar names rise after Obama pledges U.S. help for Indian solar push
Subscribe for More Information
10:28 EDTFSLRIndia's Mahnidra to add 500 MW of solar energy, Reuters says
Subscribe for More Information
09:19 EDTGSKGlaxoSmithKline announces availability of two new products for asthma
Subscribe for More Information
06:48 EDTFSLRTax credit, loan guarantee changes could hurt solar energy, NY Times says
Subscribe for More Information
January 23, 2015
08:52 EDTGSKArray BioPharma to hold a conference call
Subscribe for More Information
08:10 EDTGSKArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
07:44 EDTGSKGlaxo says now in position to deliver 'tens of thousands' of Ebola vaccine doses
Witty expects to start seeing data from trials of Ebola vaccines in next four to five months. GlaxoSmithKline CEO Andrew Witty speaking on CNBC.
06:39 EDTGSKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 22, 2015
08:20 EDTDDD3D Systems February volatility at low end of historic range
3D Systems February call option implied volatility is at 40, March is at 46; compared to its 26-week average of 47 according to Track Data. Low February option implied volatility suggests decreasing price movement into the expected release of Q4 results in late February.
January 21, 2015
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:09 EDTSSYS, DDDPiper positive on Stratasys, cautious on 3D Systems after survey
Subscribe for More Information
January 20, 2015
12:01 EDTCIDMCinedigm acquires North American rights to 10 AIP titles
Subscribe for More Information
11:03 EDTFSLRStocks with call strike movement; FSLR NE
First Solar (FSLR) January call option implied volatility increased 5% to 48, Noble Corp. (NE) June 18 call option implied volatility increased 9% to 53 according to IVolatility.
10:15 EDTDDD3D Systems call activity attributed to takeover speculation
3D Systems January weekly 29 and 30 calls are active on total call volume of 8,600 contracts (900 puts) on renewed takeover speculation. January weekly call option implied volatility is at 78, February is at 53, March is at 56; compared to its 26-week average of 47 according to Track Data. Active call volume suggests traders taking positions for price movement.
10:07 EDTDDDRumor: 3D Systems strength attributed to takeover speculation
Shares of 3D Systems are moving higher on speculation the company has hired an investment bank to review a potential sale of the company.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use